An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade
出版年份 2021 全文链接
标题
An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade
作者
关键词
-
出版物
Journal for ImmunoTherapy of Cancer
Volume 9, Issue 12, Pages e002843
出版商
BMJ
发表日期
2021-12-24
DOI
10.1136/jitc-2021-002843
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- CAR T cells in solid tumors: challenges and opportunities
- (2021) Faroogh Marofi et al. Stem Cell Research & Therapy
- Combination therapy with oncolytic viruses and immune checkpoint inhibitors
- (2020) Matthew Chiu et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade
- (2020) Shinsuke Nakao et al. Science Translational Medicine
- Intratumoral Delivery of a PD-1-blocking scFv encoded in Oncolytic HSV-1 Promotes Antitumor Immunity and Synergizes with TIGIT Blockade
- (2020) Chaolong Lin et al. Cancer Immunology Research
- Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE).
- (2020) Delvys Rodriguez-Abreu et al. JOURNAL OF CLINICAL ONCOLOGY
- Oncolytic vaccinia virus delivering tethered IL-12 enhances antitumor effects with improved safety
- (2020) Yan Ge et al. Journal for ImmunoTherapy of Cancer
- IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma
- (2020) Joe-Marc Chauvin et al. CLINICAL CANCER RESEARCH
- Oncolytic Viruses and the Immune System: The Dynamic Duo
- (2020) Ana Lemos de Matos et al. Molecular Therapy-Methods & Clinical Development
- Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics
- (2019) Zong Sheng Guo et al. Journal for ImmunoTherapy of Cancer
- Oncolytic Virus-based Cytokine Expression to Improve Immune Activity in Brain and Solid Tumors
- (2019) Taylor M. Pearl et al. Molecular Therapy-Oncolytics
- Updates to the antitumor mechanism of oncolytic virus
- (2019) Yang Bai et al. Thoracic Cancer
- DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy
- (2019) Beatriz Sanchez-Correa et al. Cancers
- Oncolytic Viruses Engineered to Enforce Leptin Expression Reprogram Tumor-Infiltrating T Cell Metabolism and Promote Tumor Clearance
- (2019) Dayana B. Rivadeneira et al. IMMUNITY
- Recombinant Adenovirus Expressing a Soluble Fusion Protein PD-1/CD137L Subverts the Suppression of CD8+ T Cells in HCC
- (2019) Yonghui Zhang et al. MOLECULAR THERAPY
- Engineering Newcastle disease virus as oncolytic vector for intratumoral delivery of immune checkpoint inhibitors and immunocytokines
- (2019) Gayathri Vijayakumar et al. JOURNAL OF VIROLOGY
- Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
- (2019) Shuang Qin et al. Molecular Cancer
- TIGIT as an emerging immune checkpoint
- (2019) H. Harjunpää et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Enhanced Therapeutic Efficacy of a Novel Oncolytic Herpes Simplex Virus Type 2 Encoding an Antibody Against Programmed Cell Death 1
- (2019) Yujie Zhu et al. Molecular Therapy-Oncolytics
- Oncolytic Viruses for Cancer Therapy: Barriers and Recent Advances
- (2019) Meijun Zheng et al. Molecular Therapy-Oncolytics
- PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy
- (2018) Dmitriy Zamarin et al. JOURNAL OF CLINICAL INVESTIGATION
- Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors
- (2018) Erhao Zhang et al. Molecular Cancer
- Oncolytic Virus Combination Therapy: Killing One Bird with Two Stones
- (2018) Nikolas Tim Martin et al. MOLECULAR THERAPY
- Superagonist IL-15-armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade
- (2018) Stacy J. Kowalsky et al. MOLECULAR THERAPY
- Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity
- (2018) Qing Zhang et al. NATURE IMMUNOLOGY
- Oncolytic Viral Therapy and the Immune System: A Double-Edged Sword Against Cancer
- (2018) Giulia Marelli et al. Frontiers in Immunology
- TIGIT: a novel immunotherapy target moving from bench to bedside
- (2018) Benjamin L. Solomon et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Tumor microenvironment remodeling by intratumoral oncolytic vaccinia virus enhances the efficacy of immune checkpoint blockade
- (2018) Hong Jae Chon et al. CLINICAL CANCER RESEARCH
- Modifying the cancer-immune set point using vaccinia virus expressing re-designed interleukin-2
- (2018) Zuqiang Liu et al. Nature Communications
- Oncolytic virus immunotherapy: future prospects for oncology
- (2018) Junaid Raja et al. Journal for ImmunoTherapy of Cancer
- Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy
- (2017) Zuqiang Liu et al. Nature Communications
- Oncolytic Viruses—Natural and Genetically Engineered Cancer Immunotherapies
- (2017) Sachin R. Jhawar et al. Frontiers in Oncology
- Oncolytic Viruses—Interaction of Virus and Tumor Cells in the Battle to Eliminate Cancer
- (2017) Anwen Howells et al. Frontiers in Oncology
- Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
- (2016) Ana C. Anderson et al. IMMUNITY
- Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma
- (2016) Igor Puzanov et al. JOURNAL OF CLINICAL ONCOLOGY
- Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition
- (2016) Patricia Kleinpeter et al. OncoImmunology
- TIGIT and PD-1 impair tumor antigen–specific CD8+ T cells in melanoma patients
- (2015) Joe-Marc Chauvin et al. JOURNAL OF CLINICAL INVESTIGATION
- TIGIT predominantly regulates the immune response via regulatory T cells
- (2015) Sema Kurtulus et al. JOURNAL OF CLINICAL INVESTIGATION
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
- (2015) Robert H.I. Andtbacka et al. JOURNAL OF CLINICAL ONCOLOGY
- Oncolytic viruses: a new class of immunotherapy drugs
- (2015) Howard L. Kaufman et al. NATURE REVIEWS DRUG DISCOVERY
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Oncolytic Viruses and Their Application to Cancer Immunotherapy
- (2014) E. A. Chiocca et al. Cancer Immunology Research
- Receptors that interact with nectin and nectin-like proteins in the immunosurveillance and immunotherapy of cancer
- (2012) Christopher J Chan et al. CURRENT OPINION IN IMMUNOLOGY
- Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4
- (2011) J D Dias et al. GENE THERAPY
- Chemokine Expression From Oncolytic Vaccinia Virus Enhances Vaccine Therapies of Cancer
- (2011) Jun Li et al. MOLECULAR THERAPY
- Functionally Distinct LAG-3 and PD-1 Subsets on Activated and Chronically Stimulated CD8 T Cells
- (2009) J. F. Grosso et al. JOURNAL OF IMMUNOLOGY
- Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial
- (2008) Byeong-Ho Park et al. LANCET ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started